Avaxia seeks collaborators who can provide financial support and expertise to enhance the success of its programs.  All programs are currently available for collaboration or license.

On August 3, 2011, Avaxia announced a collaboration with BARDA (Biomedical Advanced Research and Development Authority) for the research and development of an oral antibody therapy to mitigate the gastrointestinal damage that follows radiation exposure that might occur after a nuclear incident. The contract totals $2.9 million over two years, provided that key milestones are achieved.

For more information about opportunities to partner with Avaxia, please contact Michael Rivard, VP Corporate Development at 781-861-0062 or e-mail us at info@avaxiabiologics.com.